CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...